ArticleScientific reports2025
Lipoic acid-plumbagin conjugate protects pancreatic beta cells against high glucose-induced toxicity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic β cells that produce insulin play a significant role in maintaining glucose homeostasis. However, high glucose (HG) causes oxidative stress, which leads to pancreatic β cell dysfunction. The synthesis of lipoic acid (LA) and plumbagin (PLU) conjugate (LA-PLU) was done and characterized using (1H) NMR, (13C) NMR, LC-ESI-MS/MS, and UV-visible spectroscopy techniques. ADME analysis confirmed the drug-like properties of LA-PLU. The present study revealed the protective effect of LA-PLU conjugate against HG (25 mM)-induced oxidative stress on pancreatic β cells. Cell viability was performed on RIN-5F cells and found that LA-PLU exhibits non-toxic up to 91.23 ± 2.61% of cell viability at 12.5 µM concentration. At 12.5 µM, LA-PLU protected pancreatic β cells up to 73.45 ± 3.72% under HG conditions. LA-PLU showed a protective effect on RIN-5F cells against HG-induced DNA damage, followed by preserving mitochondrial membrane potential and decreasing reactive oxygen species formation. Further, LA-PLU showed an anti-apoptotic effect by increasing the Bcl-2 (B cell lymphoma-2) level and decreasing the apoptotic proteins [Bcl-2 associated x (Bax), and cleaved caspase-3). Hence, the overall study concludes that LA-PLU could act as a potent antioxidant that protects the RIN-5F cells under HG conditions, resulting in the maintenance of glucose homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.